Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07259317 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Adenocarcinoma
Carcinoma, Pancreatic Ductal

Interventions

DRUG: Relacorilant 150 mg once daily (QD)
DRUG: Nab-paclitaxel 100 mg/m^2
DRUG: Gemcitabine 1000 mg/m^2

Sponsor

Corcept Therapeutics